Helios Fachklinik Vogelsang-Gommern GmbH
- Address
- Sophie-Von-Boetticher-Strasse 1, Vogelsang, 39245 Gommern, Germany
Helios Fachklinik Vogelsang-Gommern GmbH - Autoimmune and Rheumatic Disease Research Center
Helios Fachklinik Vogelsang-Gommern GmbH is a specialized clinical research facility focused on advancing therapeutic options for patients with complex autoimmune and rheumatic disorders. The center demonstrates particular expertise in conducting phase 2 and phase 3 clinical trials evaluating novel biological therapies and targeted immunomodulatory agents for systemic inflammatory conditions.
- Systemic lupus erythematosus (SLE) - evaluating long-term safety and efficacy of innovative biologics including dapirolizumab pegol
- Rheumatoid arthritis - investigating novel therapeutic agents such as rosnilimab for moderate to severe disease
- Vasculitis and inflammatory myopathies - including giant cell arteritis and dermatomyositis treatment studies
The facility's research portfolio reflects a commitment to addressing unmet needs in rare and complex autoimmune conditions, with particular emphasis on evaluating combination therapies with standard of care medications and studying disease remission maintenance strategies. Their clinical trial experience spans multiple therapeutic modalities including monoclonal antibodies, pegylated biologics, and novel small molecule inhibitors targeting key inflammatory pathways in systemic rheumatic diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Boehringer Ingelheim Espana S.A.2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Boehringer Ingelheim Espana S.A.2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Helios Fachklinik Vogelsang-Gommern GmbH
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GLPG3667 once daily for 24 weeks in adult subjects with dermatomyositis | Lakefront Biotherapeutics | Phase II | Not Recruiting | Aug 2023 | Apr 2026 |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol | 2 | Unknown | 2025-11-14 | 2025-11-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.